The Real Cost of Essential Medicines: Manufacturing Economics, IP Architecture, and Procurement Strategy for WHO EML Drugs
Global Key Takeaways The WHO Essential Medicines List covers more than 500 drugs that health systems are expected to keep […]
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio
Optimization of Pharmaceutical R&D Portfolios: Strategic IP Valuation and Risk Mitigation in Regulated Markets Pharmaceutical R&D requires a capital allocation
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio Read Post »
Drugs and Devices: Comparison of European and U.S. Approval Processes
Executive Summary: The Transatlantic Bifurcation The global life sciences industry stands at a critical juncture, navigating a bipolar regulatory order
Drugs and Devices: Comparison of European and U.S. Approval Processes Read Post »
A Comprehensive Strategic Analysis of Machine Learning Applications in the Pharmaceutical Industry
Executive Summary: The Structural Redesign of an Industry The pharmaceutical sector, historically characterized by its defensive moats of intellectual property
Outsourcing Drug Development: The Definitive Pharma IP and Operations Playbook
Section 1: The Economic Architecture of Modern Drug Development The numbers that define pharmaceutical R&D productivity are brutal and well-documented.
Outsourcing Drug Development: The Definitive Pharma IP and Operations Playbook Read Post »
China’s Pharmaceutical Innovation Ecosystem: Obstacles, Opportunities, and the IP Architecture Beneath Both
Introduction China’s pharmaceutical sector completed a structural transformation in less than a decade. The country that was processing the world’s
Branded Generics: The Profit Engine Behind Off-Patent Drug Strategy
Part 1: What Branded Generics Are (and Why the Distinction Matters) Defining the Category A branded generic is a pharmaceutical
Branded Generics: The Profit Engine Behind Off-Patent Drug Strategy Read Post »
Optimizing your API strategy to deliver desired results
Section 1: Why API Strategy Is Corporate Strategy The Active Pharmaceutical Ingredient is not a line item in a chemistry
Optimizing your API strategy to deliver desired results Read Post »
Generic Drug Markets: U.S. vs. Europe. Prices, Volumes, IP Strategy, and the $445 Billion Savings Gap
Why This Comparison Matters Now The generic pharmaceutical industry generated $445 billion in U.S. system savings in 2023 alone, according
